Lexeo Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 21.68 million compared to USD 18.66 million a year ago. Basic loss per share from continuing operations was USD 0.77 compared to USD 11.58 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.1 USD | -3.36% | +5.76% | +34.76% |
Jun. 06 | HC Wainwright Initiates Lexeo Therapeutics at Buy With $22 Price Target | MT |
May. 09 | Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.76% | 617M | |
+48.73% | 56.95B | |
+39.98% | 40.26B | |
-7.07% | 39.32B | |
-4.42% | 28.37B | |
+12.45% | 26.45B | |
-18.01% | 19.41B | |
+29.40% | 12.54B | |
+25.48% | 12.21B | |
-0.43% | 12.15B |
- Stock Market
- Equities
- LXEO Stock
- News Lexeo Therapeutics, Inc.
- Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024